Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ION547 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ION547 | EXPERIMENTAL | Ascending single multiple doses of ION547 will be administered by SC injection. |
| Placebo | PLACEBO_COMPARATOR | Ascending single multiple doses of ION547-matching placebo will be administered by SC injection. |
| Name | Type | Description |
|---|---|---|
| ION547 | DRUG | ION547 will be administered by SC injection. |
| Placebo | DRUG | ION547-matching placebo will be administered by SC injection. |
Inclusion Criteria: 1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements. 2. Healthy males or females 18 to 65, inclusive, at the time of informed consent. 3. Satisfy the following: a. Femal...
ION547 is an investigational small molecule developed by Ionis Pharmaceuticals, Inc. (ticker: IONS). It has been studied in a Phase 1 clinical trial in healthy adult volunteers. Ionis has not publicly disclosed the specific disease or condition that ION547 is intended to treat.
ION547 is being developed by Ionis Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker IONS. Ionis is the sponsor of the clinical program evaluating ION547.
ION547 is in Phase 1 clinical development. Its single Phase 1 trial, NCT04934891, has been completed. Because no later-stage trials have been reported, ION547 remains an investigational drug and has not been approved by the FDA for any indication.
ION547 has been evaluated in one Phase 1 trial, NCT04934891, titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547." The trial enrolled 48 healthy adult volunteers in Canada and is now completed.
The Phase 1 trial NCT04934891 was a randomized, double-blind, placebo-controlled study of single and multiple doses of ION547. It enrolled 48 healthy volunteers of any sex, aged 18 years and older, at sites in Canada, and assessed safety, tolerability, pharmacokinetics, and pharmacodynamics.
ION547 is an investigational drug, and the condition it is intended to treat has not been disclosed. Its only reported clinical study was a Phase 1 trial in healthy volunteers, which evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics rather than efficacy in a patient population.